Trial · NCT01471730
The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery
NCT01471730, Phase 3, Completed, IRCCS Policlinico S. Donato
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. Trials, record NCT01471730. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01471730
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery
- NCT number
- NCT01471730
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 119 participants, actual
- Lead sponsor
- IRCCS Policlinico S. Donato
- Conditions
- Heart Disease
- Interventions
- Fibrinogen, Saline solution, Prothrombin complex
- First posted
- 2011-11-16
- Last updated
- 2015-03-31
- Other registries' IDs
- eudract:2011-005223-40
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Avoidance of allogeneic blood products transfusion | 30 days | Includes avoidance of packed red cells, FFP, platelet concentrates, cryoprecipitates |
| Secondary | Reduction in allogeneic blood products transfusions | 30 days | |
| Secondary | Massive blood transfusion | First postoperative 24 hours | Number of patients experiencing blood transfusion of 7 RBC units or more in the first postoperative 24 hours. |
| Secondary | Bleeding | First postoperative 12 hours | Amount of postoperative bleeding that the patients experience in the first postoperative 12 hours. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01471730
GET https://conductscience.org/api/trials/v1/NCT01471730/registered